The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016

GBI Research’s report, “The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 – Strategies to Counter Generic Erosion in Key Markets”, provides in-depth analysis of the unmet needs, drivers and barriers that impact the global ophthalmology therapeutics market. The report analyzes the ophthalmology markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
– Annualized market data for the ophthalmology market from 2001 to 2009, forecast forward to 2016.
– Analysis of the leading therapeutic segments, including glaucoma, macular degeneration, macular edema and allergic conjunctivitis.
– Analysis of the ophthalmology market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.
– Market characterization of the ophthalmology market including market size, the annual cost of therapy, sales volume and treatment usage patterns.
– Key drivers and barriers that have a significant impact on the market.
– Coverage of pipeline molecules in the various phases of drug development.
– Competitive benchmarking of leading companies such as Pfizer, Allergan, Inc., Alcon, Inc., Novartis AG, Merck & Co Inc and Roche.
– Key M&A activities that have taken place in 2009 and the licensing agreements in the 2008-2009 global ophthalmology market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
– Align your product portfolio to the markets with high growth potential.
– Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
– Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
– Develop key strategic initiatives by understanding the key focus areas of the leading companies.
– Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Content

1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 10

2 Global Ophthalmology Therapeutics Market: Introduction 13
2.1 GBI Research Report Guidance 13

3 Global Ophthalmology Therapeutics Market: Market Overview 14
3.1 Introduction 14
3.2 Revenue Forecasts for the Global Ophthalmology Therapeutics Market 14
3.2.1 Sales Value 14
3.2.2 Annual Cost of Therapy 15
3.2.3 Treatment Usage Patterns 17
3.2.4 Generics’ Share in the Global Ophthalmology Therapeutics Market 23
3.2.5 Sales of Leading Drugs 25

4 Global Ophthalmology Therapeutics Market: Therapeutic Landscape 26
4.1 Glaucoma Market 26
4.1.1 Introduction 26
4.1.2 Unmet Needs 27
4.1.3 Sales Value 28
4.1.4 Sales Volume 29
4.1.5 Annual Cost of Therapy 30
4.1.6 Treatment Usage Patterns 32
4.1.7 Geographical Segmentation 39
4.1.8 Drivers of the Glaucoma Market 41
4.1.9 Restraints for Glaucoma Market 41
4.2 Macular Edema 42
4.2.1 Introduction 42
4.2.2 Unmet Needs 42
4.2.3 Sales Value 43
4.2.4 Sales Volume 44
4.2.5 Annual Cost of Therapy 45
4.2.6 Treatment Usage Patterns 46
4.2.7 Geographical Segmentation 52
4.2.8 Drivers of the Macular Edema Market 54
4.2.9 Restraints For Macular Edema Market 54
4.3 Macular Degeneration Market 54
4.3.1 Introduction 54
4.3.2 Unmet Needs 55
4.3.3 Sales Value 55
4.3.4 Sales Volume 56
4.3.5 Annual Cost of Therapy 58
4.3.6 Treatment Usage Patterns 59
4.3.7 Geographical Segmentation 65
4.3.8 Drivers of Macular Degeneration Market 67
4.3.9 Restraints for Macular Degeneration Market 67
4.4 Allergic Conjunctivitis Market 68
4.4.1 Introduction 68
4.4.2 Unmet Needs 68
4.4.3 Sales Value 69
4.4.4 Sales Volume 70
4.4.5 Annual Cost of Therapy 71
4.4.6 Treatment Usage Patterns 72
4.4.7 Geographical Segmentation 78
4.4.8 Drivers of Allergic Conjunctivitis Market 80
4.4.9 Restraints for Allergic Conjunctivitis Market 80

5 Global Ophthalmology Therapeutics Market: Geographical Landscape 81
5.1 Geographical Break-up 81
5.2 The US 82
5.2.1 Sales Value 82
5.2.2 Annual Cost of Therapy 83
5.2.3 Treatment Usage Patterns 84
5.3 Top Five Countries in Europe 90
5.3.1 Sales Value 90
5.3.2 Annual Cost of Therapy 91
5.3.3 Treatment Usage Patterns 92
5.4 Japan 96
5.4.1 Sales Value 96
5.4.2 Annual Cost of Therapy 97
5.4.3 Treatment Usage Patterns 98

6 Global Ophthalmology Therapeutics Market: Pipeline Analysis 104
6.1 Introduction 104
6.2 Research and Development Pipeline by Phase 104
6.2.1 Research and Development Pipeline – Macular Degeneration 105
6.2.2 Research and Development Pipeline – Glaucoma 106
6.2.3 Research and Development Pipeline – Macular Edema 106
6.2.4 Research and Development Pipeline – Allergic Conjunctivitis 107
6.3 R&D Trends 107
6.3.1 New Promising Treatments for Diabetic Retinopathy 107
6.3.2 Combination Drugs Will be a Key Component of Ophthalmology Research and Development 107
6.4 Profiles of Key Drugs in the Glaucoma Pipeline 108
6.4.1 Saflutan (tafluprost) 108
6.4.2 NCX-116 (Formerly PF-03187207) 108
6.4.3 Catioprost 109
6.5 Profiles of Key Drugs in Macular Edema and Diabetic Retinopathy Pipeline 110
6.5.1 Iluvien 110
6.5.2 iCo-007 111
6.6 Profiles of Key Drugs in Macular Degeneration Pipeline 111
6.6.1 ACU-4429 111
6.6.2 AL-8309 112
6.7 Profiles of Key Drugs in Allergic Conjunctivitis Pipeline 112
6.7.1 FOV1101 (Prednisporin) 112

7 Global Ophthalmology Therapeutics Market: Competitive Landscape 113
7.1 Market Share Analysis: Ophthalmology 113
7.2 Competitive Profiling 115
7.2.1 Pfizer 115
7.2.2 Allergan, Inc. 116
7.2.3 Alcon, Inc. 118
7.2.4 Novartis AG 120
7.2.5 Merck & Co Inc 122
7.2.6 Roche 123

8 Global Ophthalmology Therapeutics Market: Strategic Consolidations 125
8.1 Overview 125
8.1.1 Valeant Pharmaceuticals International Agrees to Acquire Aton Pharma Inc 126
8.1.2 Healthcare of Today, Inc. has Acquired MacuCLEAR, Inc. 126
8.1.3 Opko Health, Inc. has Acquired Pharmacos Exakta 126
8.1.4 Sanofi-aventis Acquired Fovea Pharmaceuticals 126
8.1.5 Alcon, Inc Acquired ESBATech AG 126
8.1.6 Aton Pharma, Inc. Acquired Marketing Rights to Ophthalmology Drug 126
8.2 R&D Licensing Agreements 127
8.2.1 General 127
8.2.2 Preclinical and Discovery 127
8.2.3 Phase I 128
8.2.4 Phase II 130
8.2.5 Phase III 130
8.2.6 Approved 131

9 Global Ophthalmology Therapeutics Market: Appendix 133
9.1 Market Definitions 133
9.2 Abbreviations 133
9.3 Research Methodology 134
9.3.1 Coverage 134
9.3.2 Secondary Research 135
9.3.3 Primary Research 135
9.3.4 Forecasts 135
9.3.5 Expert Panel Validation 137
9.4 Contact Us 138
9.5 Disclaimer 138
9.6 Sources 138